Patents Assigned to Ipsen Pharma S.A.S.
  • Publication number: 20170304403
    Abstract: The present invention provides a method of ameliorating inflammation, inhibiting proinflammatory cytokine and/or chemokine expression and treating various diseases and/or conditions incidental to the onset of inflammation, in a subject in need of treatment for such conditions, by administering select analogues of native hGhrelin.
    Type: Application
    Filed: June 29, 2017
    Publication date: October 26, 2017
    Applicant: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin DONG, John E. TAYLOR, Rakesh DATTA, Michael DeWitt CULLER
  • Patent number: 9777039
    Abstract: The present invention relates to novel somatostatin analogs, dimers thereof, and methods of using the same to treat various diseases. Naturally occurring somatostatins (SSTs), which are also known as somatotropin release-inhibiting factors (SRIFs), have diverse biological effects in many cells and organs 10 throughout the body. They are produced by normal endocrine, gastrointestinal, immune and neuronal cells, as well as by certain tumors (Patel, Y. C, Frontiers in Neuroendocrinology, 20(3): 157-198 (1999); Froidevaux, et al., Biopolymers, 66(3): 161-83 (2002)).
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: October 3, 2017
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin Dong, Eric Ferrandis
  • Patent number: 9758549
    Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as obesity, diabetes mellitus and sexual dysfunction.
    Type: Grant
    Filed: February 29, 2016
    Date of Patent: September 12, 2017
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin Dong, Daniel B. Deoliveira, Jeanne Mary Comstock
  • Publication number: 20170240595
    Abstract: The present invention is directed to compounds according to formula, (R2R3)-A1-c(A2-A3-A4-A5-A6-A7-A8-A9)-A10-R1, and pharmaceutically-acceptable salts thereof that act as ligands for one or more of the melanocortin receptors, to methods of using such compounds to treat mammals and to pharmaceutical compositions comprising said compounds.
    Type: Application
    Filed: May 5, 2017
    Publication date: August 24, 2017
    Applicant: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin DONG, Jacques-Pierre MOREAU
  • Publication number: 20170240565
    Abstract: The present invention relates to novel macrocyclic compounds of formula (I) and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of LRRK2 (Leucine-Rich Repeat Kinase 2). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine or diagnostic agent, in particular for the treatment and/or diagnosis of diseases characterized by LRRK2 kinase activity such as neurological disorders including Parkinson's disease and Alzheimer's disease.
    Type: Application
    Filed: September 17, 2015
    Publication date: August 24, 2017
    Applicants: Oncodesign S.A., Ipsen Pharma S.A.S.
    Inventors: Jan Hoflack, Petra Blom, Olivier Lavergne, Sylvie Gomez
  • Patent number: 9731027
    Abstract: The present invention relates to novel somatostatin-dopamine chimeric analogs and their therapeutic uses for the inhibition, prevention, and/or treatment of neoplasia, neuroendocrine tumors, Cushing's disease/syndrome, and other conditions.
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: August 15, 2017
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin Dong, Yeelana Shen, Sun Hyuk Kim
  • Patent number: 9724397
    Abstract: The present invention relates to a parenteral, sustained and controlled release, semisolid formulation comprising an end-capped oligomer and at least one active substance without any supplementary viscosity reducing agent or excipient.
    Type: Grant
    Filed: October 26, 2007
    Date of Patent: August 8, 2017
    Assignee: IPSEN PHARMA S.A.S.
    Inventors: Roland Cherif-Cheikh, Anne-Paula De Sousa Delgado, Frédéric Lacombe, Laurence Lachamp, Didier Bourissou
  • Patent number: 9676752
    Abstract: Imidazolidine-2,4-dione derivatives of formula (I): The compounds have anti-proliferative activity and are useful for treating pathological states and diseases linked to an abnormal cell proliferation such as cancer.
    Type: Grant
    Filed: December 31, 2013
    Date of Patent: June 13, 2017
    Assignee: IPSEN PHARMA S.A.S.
    Inventors: Serge Auvin, Christophe Lanco, Qi Chao, Kaichun Gu
  • Patent number: 9603942
    Abstract: The present invention relates to novel somatostatin-dopamine chimeric analogs and their therapeutic uses for the inhibition, prevention, and/or treatment of neoplasia, neuroendocrine tumors, Cushing's disease/syndrome, and other conditions.
    Type: Grant
    Filed: February 5, 2015
    Date of Patent: March 28, 2017
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin Dong, Yeelana Shen
  • Publication number: 20170037104
    Abstract: The present invention relates to a method of treating a transient impairment of the motility of the gastrointestinal system resulting from postoperative ileus in a patient wherein said method includes the step of administering a therapeutically effective amount of a peptidyl analog of ghrelin to said patient.
    Type: Application
    Filed: October 25, 2016
    Publication date: February 9, 2017
    Applicant: Ipsen Pharma S.A.S.
    Inventors: Rakesh DATTA, Zheng Xin DONG
  • Publication number: 20160354429
    Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as insulin resistance.
    Type: Application
    Filed: August 22, 2016
    Publication date: December 8, 2016
    Applicants: Ipsen Pharma S.A.S., Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Heather A. HALEM, Michael DeWitt CULLER, Andrew A. BUTLER
  • Patent number: 9511023
    Abstract: The present invention relates to liquid or semi-solid pharmaceutical compositions, more specifically to aqueous pharmaceutical suspension or semi-solid paste containing natural mineral clays as active ingredients. These compositions are particularly useful for the treatment of acute and chronic diarrhea.
    Type: Grant
    Filed: April 29, 2011
    Date of Patent: December 6, 2016
    Assignee: IPSEN PHARMA S.A.S.
    Inventors: Béatrice Hacher, Didier Kubiak, Jeremiah Harnett, Nathalie Mondoly
  • Patent number: 9499599
    Abstract: The present invention relates to a method of treating a transient impairment of the motility of the gastrointestinal system resulting from postoperative ileus in a patient wherein said method includes the step of administering a therapeutically effective amount of a peptidyl analog of ghrelin to said patient.
    Type: Grant
    Filed: February 23, 2015
    Date of Patent: November 22, 2016
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Rakesh Datta, Zheng Xin Dong
  • Publication number: 20160311855
    Abstract: Disclosed are peptide and peptidomimetic compounds generally according to formula (I) that are useful as GHRP analogs: R1-A1-A2-A3-A4-A5-R2?? (I) wherein: A1 is Aib, Apc or Inp; A2 is D-Bal, D-Bip, D-Bpa, D-Dip, D-1Nal, D-2Nal, D-Ser(Bzl), or D-Trp; A3 is D-Bal, D-Bip, D-Bpa, D-Dip, D-1Nal, D-2Nal, D-Ser(Bzl), or D-Trp; A4 is 2Fua, Orn, 2Pal, 3Pal, 4Pal, Pff, Phe, Pim, Taz, 2Thi, 3Thi, Thr(Bzl); A5 is Apc, Dab, Dap, Lys, Orn, or deleted; R1 is hydrogen, (C1-6)alkyl, (C5-14)aryl, (C1-6)alkyl(C5-14)aryl, (C3-8)cycloakyl, or (C2-10)acyl; and R2 is OH or NH2; and pharmaceutical compositions and methods of use thereof.
    Type: Application
    Filed: July 7, 2016
    Publication date: October 27, 2016
    Applicant: Ipsen Pharma S.A.S.
    Inventor: Zheng Xin DONG
  • Patent number: 9458195
    Abstract: The present invention is directed to compounds according to formula, (R2R3)-A1-c(A2-A3-A4-A5-A6-A7-A8-A9)-A10-R1, and pharmaceutically-acceptable salts thereof that act as ligands for one or more of the melanocortin receptors, to methods of using such compounds to treat mammals and to pharmaceutical compositions comprising said compounds.
    Type: Grant
    Filed: March 29, 2011
    Date of Patent: October 4, 2016
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin Dong, Jacques-Pierre Moreau
  • Patent number: 9439943
    Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as insulin resistance.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: September 13, 2016
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Heather A. Halem, Michael DeWitt Culler, Andrew A. Butler
  • Patent number: 9415012
    Abstract: The present invention relates to a sustained-release drug composition consisting essentially of microparticles of a peptide as the active substance and a biocompatible water-soluble polymer, in particular peptide as meianocortin receptor ligand. The present invention relates also to an injection formulation comprising the sustained-release drug composition suspended in an injection medium.
    Type: Grant
    Filed: June 13, 2012
    Date of Patent: August 16, 2016
    Assignee: IPSEN PHARMA S.A.S.
    Inventors: Joël Richard, Faïza Laredj, Marie-Madeleine Baronnet, Didier Nourrisson, Jeremiah Harnett, Béatrice Hacher, Nathalie Mondoly, Laurent Bertocchi
  • Patent number: 9409948
    Abstract: Disclosed are peptide and peptidomimetic compounds generally according to formula (I) that are useful as GHRP analogs: R1-A1-A2-A3-A4-A5-R2?? (I) wherein: A1 is Aib, Apc or Inp; A2 is D-Bal, D-Bip, D-Bpa, D-Dip, D-1Nal, D-2Nal, D-Ser(Bzl), or D-Trp; A3 is D-Bal, D-Bip, D-Bpa, D-Dip, D-1Nal, D-2Nal, D-Ser(Bzl), or D-Trp; A4 is 2Fua, Orn, 2Pal, 3Pal, 4Pal, Pff, Phe, Pim, Taz, 2Thi, 3Thi, Thr(Bzl); A5 is Apc, Dab, Dap, Lys, Orn, or deleted; R1 is hydrogen, (C1-6)alkyl, (C5-14)aryl, (C1-6)alkyl(C5-14)aryl, (C3-8)cycloakyl, or (C2-10)acyl; and R2 is OH or NH2; and pharmaceutical compositions and methods of use thereof.
    Type: Grant
    Filed: October 9, 2014
    Date of Patent: August 9, 2016
    Assignee: Ipsen Pharma S.A.S.
    Inventor: Zheng Xin Dong
  • Publication number: 20160220637
    Abstract: The present invention relates to improvements in compositions containing peptides that are ligands of the GHS receptor, or pharmaceutically acceptable salts thereof, methods for preparing such compositions, and methods of using such compositions to treat mammals. In particular, the present invention relates to a pharmaceutical composition comprising a pamoate salt of H-Inp-D-Bal-D-Trp-Phe-Apc-NH2, which is a ligand of the GHS receptor and in which, after subcutaneous or intramuscular administration to a subject, the peptide forms an in situ depot at physiological pH that is slowly dissolved and released into the body fluid and bloodstream. The present invention may further comprise an organic component such as dimethylacetamide (DMA) or polyethylene glycol with an average molecular weight of lower than 1000.
    Type: Application
    Filed: January 29, 2016
    Publication date: August 4, 2016
    Applicant: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin DONG, Jundong ZHANG
  • Publication number: 20160206700
    Abstract: The present invention provides a method of ameliorating inflammation, inhibiting proinflammatory cytokine and/or chemokine expression and treating various diseases and/or conditions incidental to the onset of inflammation, in a subject in need of treatment for such conditions, by administering select analogues of native hGhrelin.
    Type: Application
    Filed: January 18, 2016
    Publication date: July 21, 2016
    Applicant: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin Dong, John E. Taylor, Rakesh Datta, Michael DeWitt Culler